A Singapore Government Agency Website 

What is the recommended interval between doses?



Unvaccinated persons aged 6 months and above should receive two initial vaccine doses at an interval of eight weeks apart.


Individuals, particularly those who are at risk for exposure to COVID-19 or severe disease, may receive the second dose earlier than eight weeks after the first dose but not less than the minimum intervals (21 days for the Pfizer-BioNTech/Comirnaty and Novavax/Nuvaxovid vaccines and 28 days for Moderna/Spikevax and Sinovac-CoronaVac vaccines).


Additional Vaccination Dose in 2023/ 2024

An additional dose of an updated vaccine for 2024 is recommended to be administered around 1 year (and no earlier than 5 months) after the last dose received. The additional dose is:

  • Recommended for all persons aged 60 years and above, medically vulnerable individuals and residents of aged care facilities;

  • Encouraged for all individuals aged 6 months and above, in particular, healthcare workers, as well as household members and caregivers of medically vulnerable individuals.



Note: Sinovac-CoronaVac vaccine continues to be included under the National Vaccination Programme (NVP). However, if there is no application for Sinovac-CoronaVac vaccine to be fully registered, NVP will lapse for Sinovac-CoronaVac vaccine, by 30 September 2024. Nevertheless, Sinovac-CoronaVac vaccine will continue to be available at private clinics which have applied to use it under the Special Access Route (SAR). Under the NVP, vaccination is free for all Singaporean Citizens, Permanent Resident, Long Term Pass Holders and certain Short Term Pass holders. However, age eligibility for the various vaccines applies.

Under the NVP, persons aged 6 months to 11 years are eligible to receive the Pfizer-BioNTech/Comirnaty and Moderna/Spikevax vaccines. Persons aged 12-17 years are eligible to receive the Pfizer-BioNTech/Comirnaty, Moderna/Spikevax or Novavax/Nuvaxovid^ vaccines. Persons aged 18 years and older are eligible to receive the Pfizer-BioNTech/Comirnaty, Moderna/Spikevax, Novavax/Nuvaxovid^ or Sinovac-CoronaVac vaccines.


^The Novavax/Nuvaxovid vaccine is currently unavailable under the NVP. Novavax is in the process of filing for regulatory approval for its updated COVID-19 XBB.1.5 vaccine formulation.

Let other citizens know if this answer was helpful
Did this answer your question?

Can’t find what you’re looking for?